Evolution of Framingham cardiovascular risk score in HIV‐infected patients initiating EFV‐ and LPV/r‐based HAART in a Latin American cohort

• DOI: 10.7448/ias.17.4.19547
• Publication Date: 2014-11-03T08:30:34Z
• Authors: Diego Cecchini; Maria Ines Mattioli; Julia Cassetti; Debora Chan; Isabel Cassetti
• Keywords: Interquartile range; Stavudine

Introduction Epidemiological studies suggest that some antiretroviral drugs may contribute to increase cardiovascular risk in HIV‐infected patients. However, data from Latin American countries are limited, as impact of HAART on remains understudied. In this context, we aimed evaluate if 10‐year Framingham Cardiovascular Risk Score (FCRS) increases patients following exposure EFV‐ and LPV/r‐based a cohort. Materials Methods Retrospective 48‐week cohort study. We reviewed clinical charts randomly selected samples initiating (according national guidelines) EFV first‐line LPV/r first‐ or second‐line (but first PI‐based) assisted at reference HIV centre Buenos Aires, Argentina (period 2004–2012). Each patient could only be included one arm. FCRS was calculated according National Institutes Health assessment tool ( http://cvdrisk.nhlbi.nih.gov/ ). Results A total 357 were included: 249 arm 108 (80 line 28 second line, but PI‐based HAART). Baseline characteristics (median, interquartile range): age, 38 (33–45) years; male, 247 (69%); viral load, 98200 (20550–306000) copies/mL; CD4 T‐cell count, 115 (60–175) cel/µL; cholesterol, 159 (135–194) mg/dL; HDL: 39 (31–41) LDL: 94 (72–123) current smoker, 29%; antihypertensive drugs: 14 (4%), diabetic: 4 (1%). Most frequent accompanying nucleoside reverse transcriptase inhibitors (NRTIs) 3TC (92%) zidovudine (AZT; 76%). low, moderate high for 93%, 7% 0% 96.7%, 1.7% On arm, an category (low high) observed 1 (0.9%) 24 weeks 6 (5,6%) 48 weeks; 5 (4.7%) decreased category. no varied 2 (3.4%) increased low (no category). Cumulative incidence overall events 1.6% 1.8% arms respectively. Probability increasing having event did not differ between significance level 5%. Conclusions similar exposed versus ClinicalTrials.gov Identifier: NCT01705873.